Acadia Signs Japan Deal for DAYBUE STIX With $30M Upfront Payment
Acadia Pharmaceuticals agreed with KYORIN Pharmaceutical on Nov. 16, 2026, to bring DAYBUE STIX to Japan for people with Rett syndrome. KYORIN will manage Japanese commercial and regulatory work, while Acadia receives $30 million upfront, may earn regulatory and sales milestones, and will share Japanese net sales. The agreement follows Acadia’s Phase 3 Japanese trial of trofinetide and builds on the drug’s approvals in the U.S., Canada, and European Union.
Why it matters
The deal gives Acadia immediate cash and potential future Japan-based payments without requiring it to lead local commercialization. KYORIN gains responsibility for the product’s Japanese launch and regulatory activities.
Key facts
- 1Acadia will receive an upfront payment of $30 million under the agreement. investing.com
- 2KYORIN will oversee commercialization and regulatory activities for DAYBUE STIX in Japan. investing.com
- 3Acadia is eligible for regulatory and sales milestone payments plus a share of net sales in Japan. investing.com
- 4DAYBUE STIX is intended to treat Rett syndrome in Japan. investing.com
- 5Trofinetide is approved in the United States, Canada, and the European Union. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.